The present invention discloses novel dual prodrug compositions of Formula
1, 1
wherein A is a single bond, --O--, or --CH.sub.2--; m and n vary from 0 to
15; p and q vary from 0 to 4; B is a single bond or --CR.sup.3R.sup.4; D
is selected from the group consisting --CO.sub.2R.sup.5, --OR.sup.6,
--OCOR.sup.7, --SO.sub.3R.sup.8, --SO.sub.2NH.sub.2,
--OPO(OR.sup.9)(OR.sup.10), --OPO(OR.sup.9)(NH.sub.2),
--OPO(OR.sup.9)--O--PO(OR.sup.10)(OR.sup.11), 2
R.sup.1 to R.sup.11 are various substituents selected to optimize the
physicochemical and biological properties such as, lipophilicity,
toxicity, bioavailability, and pharmacokinetics of compounds of Formula
1. These compounds are useful for the treatment of various cardiovascular
and neurological disorders.
